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Abstract: Bacillus Calmette–Guérin (BCG) has been studied in various cancers for its immune 
modulation. Although the mechanism is yet to be completely understood, we do have positive 
experiences in many oncological cases. Hereby, we present a case of an 82-year-old male with 
acute myeloid leukemia (AML) post allogeneic Stem Cell Transplants (AlloSCT) as a salvage 
therapy, now in remission, who presented with hematuria. Workup confirmed non-muscle 
invasive Bladder Cancer (NMIBC), for which he was treated with nine sessions of intravesical 
BCG therapy. During BCG treatment, the patient developed gradually increasing lymphocyte 
counts. Flowcytometry of a peripheral blood sample showed polyclonal cell lymphocytosis with 
CD8+ T-cell expansion. Although further work up his lymphocytosis to be polyclonal, it has 
persisted at follow-up for the last 4 years. Also, we did not find any evidence of leukemia 
recurrence at follow-up prompting us to associate the BCG use for this patient and it is role as 
immunomodulation to keep AML disease in remission. 
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Introduction
The Mycobacterium bovis strain, Bacillus Calmette–Guérin (BCG) is an attenuated, 
live vaccine developed to prevent tuberculosis. There is evidence to suggest its role 
as a cancer-fighting immunotherapy, and previously BCG has been used in the 
treatment of various malignancies such as leukemia and melanoma.1,2 Nowadays, 
intravesical administration of BCG for non-muscle invasive Bladder Cancer 
(NMIBC) is standard of care as it reduces the risk of recurrence and progression.3,4
A robust inflammatory infiltrate and T-cell expansion within bladder-draining lymph 
nodes is characteristic of responders to BCG with bladder cancer.5,6 Effector CD4+ T cells 
and CD8+ T-cells are known to be essential for tumor reduction. However, whether cross- 
antigenicity or another mechanism accounts for this effect remains under active investi-
gation. In addition, past studies on systemic BCG therapy have demonstrated its ability 
towards immune reconstitution against leukemia-associated antigen (LAA) or leukemia- 
specific antigens (LSA). In the past, scientists also attempted to develop a vaccine against 
Acute Myeloid Leukemia (AML) via epigenetic reprogramming.7 However, so far, 
vaccine against AML has only shown an increase in remission duration during the 
maintenance phase following induction and consolidation.7
Neither BCG nor other immunotherapies are currently recommended for treatment of 
AML during any phase. However, AML disease severity has been inversely correlated 
with the effectiveness of the immune response.8 Here, we describe a survivor of NMIBC 
and AML with persistent lymphocytosis 4 years after BCG therapy. He has no evidence of 
leukemia relapse or bladder cancer progression or recurrence.
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Case Presentation
A 78-year-old gentleman presented to our hospital 16 years 
ago for fever and shortness of breath of 2-week duration. 
Laboratory workup suggested pancytopenia with circulating 
blast cells. A bone marrow aspirate with biopsy was requested 
which was consistent with AML with multilineage dysplasia. 
Subsequently, the patient was treated with daunorubicin/Ara-C 
“7+3” induction chemotherapy. Repeat bone marrow biopsy 
on day 28 confirmed a complete remission (CR). This was 
followed by one cycle of consolidation therapy with high dose 
Ara-C and autologous Hemopoietic Stem Cell Transplant 
(HSCT) without complications.
A year later, the patient relapsed, as evidenced by pancy-
topenia, and had 35% blasts in the bone marrow examination. 
This time, he was treated with two cycles of the FLAG (fludar-
abine, cytarabine and filgrastim) regimen. This resulted in 
a 2nd CR that lasted until January 2009 when biopsy revealed 
tetraploid karyotype with multiple chromosomal abnormal-
ities. High dose Mitoxantrone/Cytarabine salvage therapy 
achieved a 3rd CR followed by a repeat autologous HSCT. 
His bone marrow biopsy showed 1% blasts and cytogenetics 
revealed minimal residual disease 3 months following HSCT. 
The patient was followed at a regular interval for disease 
monitoring.
Five years after 2nd HSCT, the patient’s peripheral blood 
cell counts started to fall again, and 56% blasts were noted in 
the bone marrow. Salvage therapy with decitabine was initiated 
for his refractory disease and the patient received four cycles of 
injection decitabine without severe adverse effects. He then 
underwent an allogeneic stem cell transplantation in CR4. His 
posttransplant course was complicated by reactivated 
Cytomegalovirus (CMV) antigenemia treated with ganciclo-
vir, and BK virus induced urinary tract infections treated 
symptomatically with pyridium.
For nearly the following 4 years, the patient continued 
to remain in remission from AML but developed hema-
turia as confirmed by urinary cytology. Pathology from his 
subsequent Transurethral Resection of Bladder Tumor 
(TURBT) showed G1 papillary carcinoma limited to the 
bladder lining, stage pTa. He was followed with every 3 
months surveillance cystoscopy (Figure 1).
He remained asymptomatic for the next 1 year when 
urinary symptoms returned, and five bladder tumors were 
identified. He underwent TURBT with bilateral retrograde 
pyelograms without any complications that revealed that 
the tumors were of high-grade squamous differentiation 
without muscle invasion, stage pT1. As the patient was 
now immunocompetent with recurrent pT1 superficial 
bladder cancer, an induction regimen of six weekly intra-
vesical administrations of BCG was planned. Although his 
fourth treatment was delayed due to the development of 
a non-mycobacterial pneumonia, the patient successfully 
completed the treatments without severe adverse effects.
Follow-up cystoscopy after completion of the BCG therapy 
showed no residual disease. Laboratory results at this time 
included WBC count: 11.7x103/μL (4.3–10.8x103/μL), RBC 
count: 3.63x106/μL (4.2–5.8x106/μL), platelet count: 119x103/ 
μL (140–440x103/μL), and absolute lymphocyte count: 
5.6x103/μL (0.9–3.4x103/μL). In the context of lymphocytosis, 
a peripheral blood flow cytometry was performed, which ruled 
out co-existent chronic lymphoproliferative disorders. Urinary 
symptoms and fatigue were stable allowing for three additional 
BCG treatments as consolidation therapy.
Lymphocytosis peaked at 12 x 103cells/μL, approxi-
mately 6 months following his last BCG treatment 
(Figure 2). A repeat flow cytometry confirmed a T-cell 
predominance with 5432 CD3+ cells/μL (710 −2300 
cells/μL) and a CD4:CD8 ratio of 0.22 (0.8–5.0). So far, 
the patient remains clinically asymptomatic without lym-
phadenopathy and in AML remission. The patient is being 
followed closely by hematology and urology with no 
further evidence of disease recurrence of AML or bladder 
cancer. Most recent flow cytometry done in 
September 2020 was consistent with chronic CD3+ and 
CD8+ expansion; 5712 CD3+ cells/μL (710 −2300 cells/ 
μL) with a CD4:CD8 ratio of 0.2 (0.8–5.0) (Table 1).
Discussion
Our case highlights the immunomodulating character of 
BCG in the context of AML. Recently, immunotherapy 
has been a widely accepted modality for a variety of 
cancers.9 Various microorganisms have been investigated 
as immunomodulatory agents, including BCG. The best 
evidence for its efficacy is its activity against NMIBC for 
which it is a standard of care.10
In our case, for high-grade NMIBC, our patient 
received 6 weeks of induction and 3 weeks of maintenance 
intravesical BCG installations. Even with this considered 
optimal therapy schedule, however, 30–35% of superficial 
bladder do not respond to therapy or recur while on treat-
ment. Optimizing treatment regimens to enhance response 
is an important area of contemporary research.11
Recent studies suggest that exposure to BCG induces 
epigenetic reprogramming in innate immune cells such as 
monocytes.12,13 When subjected to a subsequent pathogen 
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or cancerous process, these cells have altered metabolism 
and augmented cytokine release.
The process of immunomodulation caused by intravesical 
BCG begins when mycobacteria are internalized by urothelial 
cells by fibronectin and integrin receptors.14 Innate immune 
cells present BCG antigens, release cytokines, and mobilize 
a granulomatous infiltrate. Granulocytes, CD4+ and CD8+ 
T cells, natural killer (NK) cells and macrophages infiltrate 
the bladder, releasing a deluge of primarily TH-1 cytokines.6 
Numerous downstream pathways are activated to achieve 
tumor cell killing.
In essence, BCG alters the bladder tissue microenviron-
ment to reverse the immunosuppressive phenotype seen in 
bladder cancer. This allows innate immune cells to mount 
a vigorous secondary response against unrelated cancer 
cells.15 Stimulation of cytotoxic T lymphocytes and NK 
cells constitute as major contributors to promote anti-tumor 
effect following BCG therapy in case of bladder cancer. The 
use of BCG therapy is considered safe as BCG is live 
attenuated which considerably decreases its infection cap-
ability. But, there is a theoretical risk of increased morbidity 
and sepsis, especially in immunocompromised patients just 
like any naturally acquired mycobacteria infection.16 
However, a previous report does describe the safe utilization 
of intravesical BCG in several post-HSCT patients with 
refractory NMIBC.17
The other facts to note in our case are the persistence of 
lymphocytosis (consisting mostly of T cells that were CD3 
+CD8+ cell subtype) post BCG therapy and continued 
remission of AML disease. Prior to his NMIBC diagnosis, 
our patient was struggling with multiple relapses of his 
AML disease and required three HSCTs since the time of 
the first diagnosis in 2004. Blasts of AML are poorly immu-
nogenic and have immune-evasive properties including sup-
pression of the costimulatory ligands and MHC proteins 
required for immune activation.8 This is also one reason 
that patients who have delayed immune reconstitution fol-
lowing HSCT have a high risk of AML relapse.18 While 
there is ample evidence of immune failure in patients with 
AML, no immunotherapies are first-line treatment.
The success of HSCT depends on the Graft-vs-Leukemia 
effect when donor lymphocytes attack leukemic cells. This 
concept is utilized in some patients with Donor Lymphocyte 
Infusions (DLI).19,20 Similar functional expansion of CD8+ 
Figure 1 Disease timeline of the patient course of illness from the time of diagnosis of AML to last follow-up.
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T-cells with anti-leukemic effect has also been noted follow-
ing BCG therapy. It has been proposed that BCG injection 
promotes anti-leukemic activity by activation of the immune 
system by increasing TNF-alpha, IFN-gamma, and IL-2.21 
BCG acts as a Toll-like receptor agonist and stimulates TLR2 
and TRL4. TLR activation in turn enhances NK cell- 
mediated cytotoxicity, enhancing the MHC class I on leuke-
mic cells, that ultimately leads to leukemic cell apoptosis.22 
We hypothesize that the persistent lymphocytosis with T-cell 
predominance and Toll-like receptor agonism secondary to 
BCG therapy together with nonspecific effect of live vaccine 
or trained immunity contributed to continued anti-leukemic 
effect against AML in our patient.
Conclusion
Immuno-oncology is an evolving field in cancer medicine. 
Understanding of the complex mechanism of BCG therapy 
in modulating the immune system is the need of the hour. 
This case suggests the need for further basic and clinical 
research to develop new treatment strategies for patients 
suffering from various malignancies.
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Figure 2 Trend of complete blood count parameters, and their association with BCG vaccinations. (× 103 cells/μL) 
Abbreviations: WBC, whole blood count; ALC, absolute lymphocyte count; ANC, absolute neutrophil count.
Table 1 Flow Cytometry Results at Various Intervals Showing 
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